Since 2009, Cochrane meta-analyses have confirmed the efficacy and safety of SLIT for seasonal and perennial allergic rhinitis [1] and conjunctivitis [2]. Several large ‘definitive’ trials have now confirmed the efficacy and safety for seasonal rhinitis in both children and adults. Long-term benefits of SLIT for at least 1 [3] or 2 [4] years following discontinuation of treatment have been demonstrated in 2 large independent trials of immunotherapy with grass pollen allergen tablets in adults. These studies provide evidence for long-term disease remission and disease modification consistent with the induction of antigen-specific tolerance.